{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Katie", "organization": "", "rank": 1, "lastname": "THOMAS"}, {"role": "reported", "firstname": "Chad", "organization": "", "rank": 2, "lastname": "BRAY"}], "original": "By KATIE THOMAS and CHAD BRAY"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "Pfizer, in wake of failed $152 billion merger with Allergan, may break itself apart by end of 2016; some analysts say two smaller companies would be worth more than one big one; Pfizer's options are limited by new rules intended to restrict inversions.", "multimedia": [{"type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/db-pfizer2/db-pfizer2-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "407"}, "width": 600, "subtype": "xlarge", "height": 407}, {"type": "image", "url": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/db-pfizer2/db-pfizer2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "Pfizer Weighs Split as Allergan Deal Collapses", "main": "Pfizer Faces Limited Options After Its Dead Deal With Allergan"}, "print_page": "1", "keywords": [{"value": "Pfizer Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "ALLERGAN INC", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Corporate Taxes", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Allergan Inc", "is_major": "Y", "rank": "7", "name": "organizations"}], "snippet": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "source": "The New York Times", "lead_paragraph": "The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.", "word_count": "929", "pub_date": "2016-04-07T04:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html", "_id": "5704f14c38f0d848959befb0"}